Demant has signed an agreement to sell Oticon Medical to Impilo for a total contractual consideration of up to DKK 600 million, thereby concluding the process of divesting its Hearing Implants business area. 

The agreement ensures the continuity of Oticon Medical’s business operations, its sustained strong position in the market, further growth as well as investments in future innovation for the benefit of customers and patients. 

“I’m very happy that Impilo is taking over the ownership of Oticon Medical. Impilo is a Nordic company that knows the healthcare – and especially the MedTech – sector very well. They have a long-term perspective, and I’m confident that Oticon Medical will continue to prosper under its new ownership. Oticon Medical is leaving Demant in good shape, as the company has delivered good growth over the years and recently enhanced its product portfolio with the launch of the flagship product, Sentio. Demant is committed to supporting the transition of the business for the benefit of customers, patients and employees,” says Søren Nielsen, President & CEO of Demant. 

As part of the agreement – and to ensure business continuity – Demant will support Impilo for a defined period of time, as they develop Oticon Medical into a stand-alone business. 

These transitional services will include jointly developing next-generation products, supplying existing and future sound processors and providing local sales and customer support as well as administrative services, until such functions are established in Oticon Medical. 

We are thrilled to acquire Oticon Medical from Demant. Under Demant's leadership, Oticon Medical has established itself as a global leader in the bone anchored hearing systems (BAHS) market, renowned for its innovation and unwavering commitment to patient care. This acquisition marks an exciting new chapter for Oticon Medical, positioning the company for even greater growth and long-term success. In close partnership with Demant, we look forward to investing in and accelerating the development of cutting-edge BAHS solutions to further enhance patient outcomes worldwide,” says Fredrik Strömholm, Managing Partner at Impilo

 

 

Back to latest news